The White House Cancer Moonshot initiative has announced a new public-private partnership to boost innovation in the fight against cancer.
CancerX will be co-hosted by the Digital Medicine Society (DiMe) and Moffitt Cancer Center. It blends DiMe’s expertise in convening cross-disciplinary groups to develop clinical-quality resources on a tech timeline with Moffitt’s top research and care experts.
The initiative is open to all those working in the field who are committed to working collaboratively and share a vision of unleashing the power of innovation to design and create a future that’s free of the burden of cancer.
SimBioSys will be one of the founding members of the CancerX initiative. “As a trusted TechBio company focused on precision medicine solutions using AI and data science to solve the spatial biophysics challenges of tumour heterogeneity, I am proud of this impactful partnership with CancerX that serves to accelerate our scientific capabilities and enhance medical knowledge to serve patients,” said Anu Antony, Surgeon and Chief Medical Officer at SimBioSys.
Drawing inspiration from the effective approaches employed by established HHS InnovationX programme accelerators like KidneyX and PandemicX, CancerX will build upon their previous models. By supporting start-ups in scaling their operations and emphasising health equity, CancerX aims to announce their first demonstration project in April 2024.
Edited by Diana Spencer, Senior Digital Content Editor, Drug Discovery World
